{
  "symbol": "ISRG",
  "year": 2023,
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1377,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.257
  },
  "top_positive": [
    {
      "sent": "CONSOLIDATED BALANCE SHEETS (IN MILLIONS, EXCEPT PAR VALUE AMOUNTS) December 31, 2022 2021 ASSETS Current assets: Cash and cash equivalents $ 1,581.2 $ 1,290.9 Short-term investments 2,536.7 2,913.1 Accounts receivable, net of allowances of $ 22.4 and $ 20.2 as of December 31, 2022, and 2021, respectively 942.1 782.7 Inventory 893.2 587.1 Prepaids and other current assets 299.8 271.1 Total current assets 6,253.0 5,844.9 Property, plant, and equipment, net 2,374.2 1,876.4 Long-term investments 2,623.6 4,415.5 Deferred tax assets 664.6 441.4 Intangible and other assets, net 710.1 633.2 Goodwill 348.5 343.6 Total assets $ 12,974.0 $ 13,555.0 LIABILITIES AND STOCKHOLDERS\u2019 EQUITY Current liabilities: Accounts payable $ 147.0 $ 121.2 Accrued compensation and employee benefits 401.6 350.1 Deferred revenue 397.3 377.2 Other accrued liabilities 476.2 301.3 Total current liabilities 1,422.1 1,149.8 Other long-term liabilities 439.3 453.7 Total liabilities 1,861.4 1,603.5 Commitments and contingencies (Note 8) Stockholders\u2019 equity: Preferred stock, 2.5 shares authorized, $ 0.001 par value, issuable in series; no shares issued and outstanding as of December 31, 2022, and 2021 \u2014 \u2014 Common stock, 600.0 shares authorized, $ 0.001 par value, 350.0 shares and 357.7 shares issued and outstanding as of December 31, 2022, and 2021, respectively 0.4 0.4 Additional paid-in capital 7,703.9 7,164.0 Retained earnings 3,500.1 4,760.9 Accumulated other comprehensive loss ( 162.5 ) ( 24.2 ) Total Intuitive Surgical, Inc.",
      "score": 0.9854
    },
    {
      "sent": "We have a four-part strategy to guide our I&D progress: ensuring an inclusive experience, where employees from all backgrounds feel welcome, supported, and valued; building a diverse workforce to fuel innovation and better mirror the patients we serve; continuously investing in and enhancing the fairness of our people practices and sharing progress; and strengthening industry engagement through collaboration with the healthcare community, diversity-focused organizations, and shareholders to drive positive change.",
      "score": 0.9849
    },
    {
      "sent": "We have a four-part strategy to guide our I&D progress: ensuring an inclusive experience, where employees from all backgrounds feel welcome, supported, and valued; building a diverse workforce to fuel innovation and better mirror the patients we serve; continuously investing in and enhancing the fairness of our people practices and sharing progress; and strengthening industry engagement through collaboration with the healthcare community, diversity-focused organizations, and shareholders to drive positive change.",
      "score": 0.9849
    }
  ],
  "top_negative": [
    {
      "sent": "These requirements include establishment registration and device listing with the FDA; compliance with medical device reporting regulations, which require that manufacturers report to the FDA if their device caused or contributed, or may have caused or contributed, to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; compliance with corrections and removal reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FFDCA that may present a risk to health; the FDA\u2019s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.",
      "score": -0.9578
    },
    {
      "sent": "These requirements include establishment registration and device listing with the FDA; compliance with medical device reporting regulations, which require that manufacturers report to the FDA if their device caused or contributed, or may have caused or contributed, to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; compliance with corrections and removal reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FFDCA that may present a risk to health; the FDA\u2019s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.",
      "score": -0.9578
    },
    {
      "sent": "If the FDA determines that a manufacturer has failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions: \u2022 warning letters, untitled letters, fines, injunctions, consent decrees, administrative penalties, and civil or criminal penalties; \u2022 recalls, withdrawals, or administrative detention or seizure of our products; \u2022 operating restrictions or partial suspension or total shutdown of production; \u2022 refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified products; \u2022 withdrawing 510(k) clearances or PMA approvals that have already been granted; 16 Table of Contents \u2022 refusal to grant export approvals for our products; or \u2022 criminal prosecution.",
      "score": -0.9382
    }
  ],
  "forward_snippets": [
    "and its impact on hospital spending, reimbursement, and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; the timing and success of product development and market acceptance of developed products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including the joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; our completion of and ability to successfully integrate acquisitions, including Orpheus Medical; procedure counts; intellectual property positions and litigation; competition in the medical device industry and in the specific markets of surgery in which we operate; risks associated with our operations and any expansion outside of the United States; unanticipated manufacturing disruptions or the inability to meet demand for products; our reliance on sole and single source suppliers; the results of legal proceedings to which we are or may become a party, including, but not limited to, product liability claims; adverse publicity regarding us and the safety of our products and adequacy of training; the impact of changes to tax legislation, guidance, and interpretations; changes in tariffs, trade barriers, and regulatory requirements; and other risks and uncertainties, including those listed under the caption \u201cRisk Factors.\u201d Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict.",
    "\u2022 If our products do not achieve and maintain market acceptance, we will not be able to generate the revenue necessary to support our business.",
    "and its impact on hospital spending, reimbursement, and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; the timing and success of product development and market acceptance of developed products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including the joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; our completion of and ability to successfully integrate acquisitions, including Orpheus Medical; procedure counts; intellectual property positions and litigation; competition in the medical device industry and in the specific markets of surgery in which we operate; risks associated with our operations and any expansion outside of the United States; unanticipated manufacturing disruptions or the inability to meet demand for products; our reliance on sole and single source suppliers; the results of legal proceedings to which we are or may become a party, including, but not limited to, product liability claims; adverse publicity regarding us and the safety of our products and adequacy of training; the impact of changes to tax legislation, guidance, and interpretations; changes in tariffs, trade barriers, and regulatory requirements; and other risks and uncertainties, including those listed under the caption \u201cRisk Factors.\u201d Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict.",
    "\u2022 If our products do not achieve and maintain market acceptance, we will not be able to generate the revenue necessary to support our business.",
    "and its impact on hospital spending, reimbursement, and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; the timing and success of product development and market acceptance of developed products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including the joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; our completion of and ability to successfully integrate acquisitions, including Orpheus Medical; procedure counts; intellectual property positions and litigation; competition in the medical device industry and in the specific markets of surgery in which we operate; risks associated with our operations and any expansion outside of the United States; unanticipated manufacturing disruptions or the inability to meet demand for products; our reliance on sole and single source suppliers; the results of legal proceedings to which we are or may become a party, including, but not limited to, product liability claims; adverse publicity regarding us and the safety of our products and adequacy of training; the impact of changes to tax legislation, guidance, and interpretations; changes in tariffs, trade barriers, and regulatory requirements; and other risks and uncertainties, including those listed under the caption \u201cRisk Factors.\u201d Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict."
  ]
}